Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Shire PLC Add to portfolio

LON100:SHP, Apr 25, 02:41 UTC

Latest LON100:SHP News

Filter your feed

Apply Filter

Friday, March 29


News

Agoraphobia Market Detailed Report With Growth Opportunity by Major Players - Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Pfizer, GlaxoSmithKline, Etc.

SHP PFE +6 more SHP PFE BMY GSK AZN AZN LLY GSK

Agoraphobia Market Detailed Report With Growth Opportunity by Major Players - Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Pfizer, GlaxoSmithKline, Etc. The report contains pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. The statistics are represented in graphical format for a clear understanding on facts and figures. For More Information On This Report, Please Visit www.upmarketresearch.com/home/enquiry_before_buying/85882.

Read Full Details

Story Sources

openpr.com openpr.com
Topics:
  • Business
  • Health
  • Financial
  • Science

Monday, March 18


News

Shire scurries for cash as Chevron shaves $5.2 million off land rates bill

SHP CVX

Shire scurries for cash as Chevron shaves $5.2 million off land rates bill. The shire said the ruling would also impact the last year and this year’s rates bills for Wheatstone, and they expected it to flow on to Barrow Island, where the company’s Gorgon gas operation is located. Chevron provides about 40 per cent of the shire’s total rates revenue so the loss would hit the shire hard. Chevron pointed to the more than $250 million spent on infrastructure in the town of Onslow and $455 million spent in local businesses since 2011 thanks to Wheatstone.

Read Full Details

Topics:
  • Business
  • Financial

Friday, March 08


News

Shire Plc (SHPG) Shareholder Odey Asset Management Group LTD Decreased Stake

SHP

According to 2018Q4 SEC filling the Odey Asset Management Group Ltd decreased its stake in Shire Plc (SHPG) by 47.51%. By selling 176,972 shares Odey Asset Management Group Ltd made the stock with 0.00%. Odey Asset Management Group Ltd increased its stake in Banco Macro Sa (NYSE:BMA) by 734,101 shares to 1.88 million shares, valued at $83.12 million in 2018Q4, according to the filing. It operates about $1.13 billion US Long portfolio. For a total of 60,350 shares it increased its holding in Microsoft Corp (NASDAQ:MSFT) by 33,350 shares in the quarter, and has risen its stake in Frontline Ltd. Another two news for Shire plc (NASDAQ:SHPG) were recently posted by: Nasdaq.com on December 18, 2018 with title “Shire (SHPG) Shares Cross Below 200 DMA – Nasdaq”.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, March 06


News

Global dry eye disease Market Report 2019 Companies included Allergan plc, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A., FCI S.A.S., Shire plc and Others - openPR

SHP AGN

Global dry eye disease Market Report 2019 Companies included Allergan plc, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A., FCI S.A.S., Shire plc and Others. The dry eye disease market delivers a wide array of primary and secondary data with respect to regional and global market. In-depth analysis of numerous components has been studied in the report including price and gross margin, capacity, production, revenue, current geographical zones, technology, demand-supply, consumption, import, export. In addition to this, the study provides Porters five forces analysis, PESTEL analysis and industry chain analysis of the dry eye disease market to gain the impact of various factors such as bargaining power of suppliers, competitive rivalry, threat of new entrants, threat of substitutes, and bargaining power of buyers on the growth of dry eye disease market.

Read Full Details

Story Sources

openpr.com openpr.com
Topics:
  • Business
  • Health
  • Financial
  • Science

Saturday, March 02


News

Reviewing Autolus Therapeutics plc (AUTL)'s and Shire plc (NASDAQ:SHPG)'s results

SHP

This is therefore a comparing of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Autolus Therapeutics plc (NASDAQ:AUTL) and Shire plc (NASDAQ:SHPG). The two are both Biotechnology companies that compete with one another. Meanwhile, Shire plc’s average target price is $196, while its potential upside is 9.38%. Autolus Therapeutics plc and Shire plc has shares owned by institutional investors as follows: 45.31% and 22.9%.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Imprimis Pharmaceuticals Inc. (IMMY) and Shire plc (NASDAQ:SHPG) Contrasting side by side

SHP

The two are both Biotechnology companies that compete with one another. Table 2 demonstrates the return on equity, return on assets and net margins of Imprimis Pharmaceuticals Inc. and Shire plc. Imprimis Pharmaceuticals Inc.’s volatility measures that it’s 187.00% less volatile than Standard and Poor’s 500 due to its -0.87 beta. Imprimis Pharmaceuticals Inc. can pay off short and long-term obligations better than Shire plc.

Read Full Details

Topics:
  • Business
  • Health

Monday, February 25


News

FTC loses Shire appeal, losing round in fight against citizen petition abuse

SHP

Visit our Privacy Policy to learn more or manage your personal preferences in our Cookie Consent Tool. FTC loses Shire appeal, losing round in fight against citizen petition abuse. WASHINGTON (Reuters) - An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market. The agency had objected to ViroPharma, which Shire acquired in 2014, filing 46 "citizen petitions" and other filings between 2006 and 2012 to the U.S. Food and Drug Administration regarding generic equivalents to its antibiotic Vancocin HCl, on the grounds that it resulted in delayed sale of a generic version. But while the appeals court acknowledged that the delayed entry meant "hundreds of millions of dollars in profits," it said that the petitioning activity had ceased and thus the company was not in violation of the law.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Wednesday, February 20


News

EyePoint Pharmaceuticals Inc. (EYPT) and Shire plc (NASDAQ:SHPG) Contrasting side by side

SHP

Both EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) and Shire plc (NASDAQ:SHPG) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. Demonstrates EyePoint Pharmaceuticals Inc. and Shire plc earnings per share, gross revenue and valuation. EyePoint Pharmaceuticals Inc. can pay off short and long-term obligations better than Shire plc.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, February 15


News

Shire plc (SHPG)'s Financial Results Comparing With XOMA Corporation (NASDAQ:XOMA)

SHP

Both Shire plc (NASDAQ:SHPG) and XOMA Corporation (NASDAQ:XOMA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. Table 1 shows the gross revenue, earnings per share and valuation for Shire plc and XOMA Corporation. XOMA Corporation therefore has a better chance of paying off short and long-term obligations compared to Shire plc.

Read Full Details

Topics:
  • Business
  • Health

Wednesday, January 23


News

Noteworthy Stocks to Watch for: AMREP Corporation (NYSE:AXR) & Shire plc (NASDAQ:SHPG)

SHP

Noteworthy Stocks to Watch for: AMREP Corporation (NYSE:AXR) & Shire plc (NASDAQ:SHPG). AMREP CORP.is a real estate developer and builder of housing, national distributor of magazines and a provider of subscription fulfillment services for publishers. It is the developer and major builder of single-family homes at Rio Rancho, New Mexico and more recently has entered the Denver, Colorado home-building market. The 1 analysts offering 12-month price forecasts for AMREP Corp have a median target of 9.25, with a high estimate of 9.25 and a low estimate of 9.25.

Read Full Details

Topics:
  • Business
  • Financial